Alexandria, VA (PRWEB) November 21, 2012
The Mesothelioma Applied Research Foundation (Meso Foundation) is proud to announce the addition of new board members to its Board of Directors.
Mike Becich, MD, PhD, Terry Lynch, and Michael Lagana became official board members this past October, and will be joined in January by Jocelyn Farrar, DNP, General H. Steven Blum, Ted Lackner, and Erica Iacono.
The Meso Foundation, a 501(c)3 non-profit organization, is governed by its Board of Directors which, as a body, charts the course for the organization, its mission, and its goals. The Board is made up of mesothelioma doctors, researchers, patients, family members, and other members of the community who, through their expertise and personal connections to mesothelioma, aid in fulfilling the mission of the Foundation. All Meso Foundation Board members are volunteers and do not receive compensation for their time.
The new board members join Hanne Mintz, Axel Hanauske, MD, PhD, Don Bendix, David Ettinger, MD, Lee Krug, MD, Richard Mosca, and Leon Pendarvis.
Mesothelioma, a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos is considered one of the most aggressive of all cancers. Approximately 3,000 Americans are diagnosed with mesothelioma every year, but unlike most other cancers, for mesothelioma there is only one approved, marginally effective, treatment regimen.
ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by it. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish more effective treatments for mesothelioma and, someday, a cure for this rare and aggressive cancer. To date, the Foundation has awarded over $7.6 million to research.
More information is available at http://www.curemeso.org.